Toronto-based Noa Therapeutics, pioneering biased engagement of the aryl hydrocarbon receptor (AhR), secured a Catalyst Research Grant from the National Eczema Association to study its lead compound’s effects in atopic dermatitis. The Johns Hopkins University Department of Dermatology will evaluate the compound’s impact on inflammatory pathways in preclinical models, bolstering Noa’s platform development for eczema and other chronic inflammatory conditions with high unmet medical needs.